Plasminogen activator inhibitor-1: The double-edged sword in apoptosis

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2008: 100/6 (Dec) pp. 955-1217
Pages: 1029-1036

Plasminogen activator inhibitor-1: The double-edged sword in apoptosis

Rashna D. Balsara; Victoria A. Ploplis

W. M. Keck Center for Transgene Research, Department of Chemistry and Biochemistry, and Notre Dame Cancer Institute, University of Notre Dame, Indiana, USA


Plasminogen activator inhibitors, apoptosis, fibrinolysis inhibitors


Plasminogen activator inhibitor type-1 (PAI-1) is a multi-functional protein. It is a fast-acting inhibitor of plasminogen activators; urokinase-plasminogen activator and tissue type plasminogen activator, and also plays an important role in regulating cell proliferation, adhesion, migration, and signal transduction pathways.These biological events are important processes during angiogenesis and restenosis. PAI-1 has been shown to regulate proliferation, migration, and apoptosis of vascular smooth muscle cells and endothelial cells.The ability of PAI-1 to regulate cellular proliferation and migration has been attributed to its ability to control plasmin production, modify signaling pathways, and its inherent multifactorial ability to bind to vitronectin and lipoprotein receptor-related protein.However,the mechanism by which PAI-1 regulates the apoptotic pathway is not well understood. Evidence from the literature suggests that PAI-1 or its deficiency alters key signalling pathways, such as the PI3-k/Akt and the Jak/STAT pathways, and is involved in maintaining endothelial cell integrity thereby regulating cell death.Other investigators have demonstrated that PAI-1 directly binds to caspases as a mechanism of PAI-1-mediated cellular apoptosis. Moreover, results from studies assessing the role of PAI-1 in apoptosis have suggested that PAI-1 can exert pathogenic or protective effects, which may be related to the disease model or type of injury employed.

You may also be interested in...

Patrick Rossignol1– 4, Eduardo Anglès-Cano 5, 6, Henri Roger Lijnen1

Thromb Haemost 2006 96 5: 665-670


Elitsa Y. Dimova; Thomas Kietzmann

Thromb Haemost 2008 100 6: 992-1006

Sanjiv Baxi 1, David L. Crandall 3, Thomas R. Meier*,1,2, Shirley Wrobleski 1, Angela Hawley 1, Diana Farris 1, Hassan Elokdah4†, Robert Sigler 5, Robert G. Schaub**, 3, Thomas Wakefield 1, Daniel Myers 1, 2

Thromb Haemost 2008 99 4: 749-758